Autopsy report · NCT01439789

Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

“Sponsor has designed another study with different endpoint to replace the current study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year before it stopped.
• 146 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Zensun Sci. & Tech. Co., Ltd.

Sponsor type

Industry

Conditions

Chronic Heart Failure

Interventions

rhNRG-1; Placebo

Participants

146

Sites

21

Countries

China

Trials that died the same way

• Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion
  “Sponsor preferred a better study design” (76% match in meaning)
• Evaluation of Tissue Oxygen Levels During Breast Reconstruction With a New Surgical Device
  “Sponsor decision to end study.” (70% match in meaning)
• Evaluating Return to Continence and Potency Following Radical Prostatectomy
  “The sponsor decided to not move forward with this study” (70% match in meaning)
• Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
  “Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.” (70% match in meaning)
• Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults
  “Sponsor changed their study product and halted study.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.